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CC chemokine ligand 2 (CCL2) or mono-
cyte chemoattractant protein-1 (MCP-1)
is an important chemoattractant for
monocytes and macrophages (Deshmane
et al, 2009). CCL2 is the main ligand for
the chemokine receptor CCR2, which
mediates CCL2’s biological activity.
CCR2 is a seven transmembrane span-
ning Gai protein-coupled receptor
(GPCR) constitutively expressed at high
levels on monocytes and macrophages.
CCL2expression isinducedinavarietyof
tissue resident cells (e.g. endothelial
cells) and immune cells (e.g. macro-
phages) by inﬂammatory mediators (e.g.
TNF, LPS and IFNg). CCL2 mobilizes
monocytes out of the bone marrow and
recruits circulating monocytes into sites
of infection and inﬂammation. Perhaps
more than any other chemokine system,
CCL2 and CCR2 have been shown to play
important pathological roles in vivo in
murine models of disease. For example,
in murine models of atherosclerosis,
experimental autoimmune encephalo-
myelitis and obesity-induced diabetes,
mice deﬁcient in CCL2 and/or CCR2 have
markedly reduced monocyte accumula-
tion in diseased tissue and are protected
from disease (Charo & Ransohoff, 2006).
Murine studies have also demonstrated
the importance of CCL2 in malignancy
and metastasis, including a recent study
demonstrating a role for CCL2 in recruit-
ing inﬂammatory monocytes into
tumours, which facilitated breast cancer
metastasis (Qian et al, 2011).
» ...inhibiting CCL2 and
CCR2 is still a very active
area for drug development
with potential application for
a multitude of important
chronic human diseases.«
Inhibiting CCL2 and CCR2 activity has
thus been thought to be a promising
new approach for treating inﬂammatory
diseases. Antibody or small molecule
chemical blockade of CCL2–CCR2
signalling is one strategy for therapeutic
intervention that has shown promise in
animal models of inﬂammatory diseases.
However, this approach has not yet
translated to effective human therapies.
The reasons for the lack of efﬁcacy in the
clinic are not known and may relate
to inappropriate disease indication, inher-
ent limitations of the drug being tested or
t h et i m i n go fd r u ga d m i n i s t r a t i o n( S c h a l l
& Proudfoot, 2011). For example, anti-
CCR2 antibodies were effective for pro-
phylaxis of inﬂammatory arthritis in a
murine model but actually worsened
disease when used in a therapeutic
context (Bruhl et al, 2004), highlighting
the complexity of targeting chemokines to
treat disease. While anti-CCL2 therapies
have not yet made their way to the clinic,
other effective therapies may derive some
of their therapeutic efﬁcacy by indirectly
inhibiting CCL2 expression, such as the
anti-TNF agents (Taylor et al, 2000).
In addition, potential complications of
inhibiting CCL2 and CCR2 need to be
considered since this chemokine system
has been shown to play important roles in
monocyte-mediated host defense. For
example, inhibition of the CCL2–CCR2
chemokineaxishasthepotentialtoimpair
host defenses against pathogens, as has
been demonstrated in murine models of
Listeria monocytogenes, Mycobacteria
tuberculosis, Toxoplasma gondii and
Cryptococcal neoformins infection, or
impair the immune response to sterile
inﬂammation, as has been demonstrated
in murine models of Alzheimer’s disease
and macular degeneration (Ambati et al,
2003; El Khoury et al, 2007; Serbina et al,
2008). Nonetheless, inhibiting CCL2 and
CCR2 is still a very active area for drug
development with potential application
for a multitude of important chronic
humandiseases.Newtherapiesthattarget
CCL2 and CCR2 are on the horizon, but
whether they can combine sufﬁcient
efﬁcacy with ample safety remains to be
seen. The elucidation of new mechanisms
ofCCL2regulation,suchastheglutaminyl
cyclase pathway, presents a new option
for chemokine-targeted therapeutics.
In this issue of EMBO Molecular
Medicine, Cynis et al present evidence
that enzymes, such as metalloenzyme
transferases, speciﬁcally glutaminyl
cyclase (QPCT, QC) and iso-glutaminyl
cyclase(QPCTL, isoQC), playaroleinthe
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catalysing the formation of N-terminal
pyroglutamate (pE), which confers resis-
tance against aminopeptidase degrada-
tion (Cynis et al, 2011). N-terminal pE
CCL2 (pE
1-CCL2) was as potent a CCR2
ligand and was as active in chemotaxis
assays as the mature uncyclized form of
CCL2 (Q
1-CCL2). The uncyclized form of
CCL2, however, was much more suscep-
tible to degradation by aminopeptidases,
such as dipeptidyl peptidase-4 (DDP-4).
N-terminally degraded forms of CCL2
have markedly diminished biological
activity. Both pE
1-CCL2 and Q
1-CCL2
were secreted in equal amounts from
LPS stimulated cells, and isoQC was
found to be the enzyme responsible for
the N-terminal cyclic conversion of
Q
1-CCL2 to pE
1-CCL2. If formation of
pE was prevented by inhibiting isoQC,
CCL2 was more prone to N-terminal
degradation, which resulted in less func-
tionalCCL2activity.Thishadtheneteffect
ofdecreasingmonocyteinﬁltrationin vivo,
resulting in decreased lung inﬂammation,
thioglycollate-induced peritonitis and
atherosclerosis in murine disease models
(Fig 1). Thus, the inhibition of the enzyme
isoQC resulted in less functional CCL2
activity in vivo and decreased monocyte
recruitment into sites of inﬂammation.
Understanding the structure–function
relationship of chemokines has helped to
elucidate the importance of the N-termi-
nus. Important structural features of
chemokines include a free and ﬂexible
N-terminal domain, three antiparallel
b-sheets, an N-loop region that follows
the ﬁrst two cysteines and connects
the N terminus to the b-sheet region, a
C-terminal a-helix and four conserved
cysteine residues involved in two intra-
chain disulphide bonds that stabilize the
‘chemokine structure’ (Fernandez &
Lolis, 2002). The importance of the N-
terminus for chemokine function is
suggested by the ‘two-step’ model of
chemokine ligand binding and receptor
activation (Fernandez & Lolis, 2002). In
this model, the ﬁrst step is chemokine
ligand binding to the chemokine
receptor,whichleadstoaconformational
change in the GPCR. The second step is
activation of the GPCR by the N-terminus
of the chemokine, which interacts with a
deﬁned region within the GPCR trans-
membrane helices. This results in signal
transduction through G proteins and a
cascade of numerous downstream effec-
tor molecules that results in directed cell
migration. The strength of signal ampli-
ﬁcation is determined by the stability of
the ligand–receptor complex and recep-
tor–effector protein complexes. Thus, the
N-terminus plays a critically important
role in initiating this activation and
ampliﬁcation process.
Modiﬁcation of the N-terminus has
been shown to abrogate chemokine
activityand,insomecases,evengenerate
competitive antagonists. This has been
shown to be the case for several CC
chemokines, including CCL2, CCL5,
CCL11 and CCL26 (Fernandez & Lolis,
2002). Elimination of the N-terminal
glutamate of CCL2 resulted in reduced
chemokine activity, while truncation of
additional N-terminal residues resulted
the generation of a CCR2 antagonist
(Deshmane et al, 2009). Furthermore,
removal of N-terminal residues 2–8
resulted in a dominant negative mutant
that formed a heterodimer with full
length mature CCL2 and abrogated
its activity. This may explain why
inhibiting isoQC was so effective at
neutralizing CCL2 activity in vivo as
uncyclized forms of CCL2, which are
susceptible to N-terminal degradation,
have the potential to act as dominant
negatives in vivo. N-terminal modiﬁca-
tions of other CC chemokines, such
as CCL5 (RANTES), also modulated
its biological activity. For example,
addition of an N-terminal methionine,
truncation of two N-terminal residues
or modiﬁcation the N-terminal of
CCL5 with aminooxypentane generated
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Figure 1. Q
1-CCL2, the mature uncyclized form of CCL2, is converted to cyclized pE
1-CCL2 by
iso-glutaminyl cyclase (isoQC). Cyclized pE
1-CCL2 is as potent a CCR2 ligand and inducer of moncyte
chemotaxis as Q
1-CCL2. However, Q
1-CCL2 is susceptible to degradation by aminopeptidases, such as
DDP-4, which generates products with much weaker biological activity (e.g.D
3-CCL2). In contrast,
cyclized pE
1-CCL2 is resistant to N-terminal proteolytic processing and thus maintains its potency and
activity. Inhibition of isoQC enzymatic activity using QC/isoQC inhibitors results in decreased levels of
pE
1-CCL2, corresponding increased levels of Q
1-CCL2 and subsequent degradation to less active CCL2
variants.
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receptors. Studies have revealed that the
N-terminus of CCL11 (eotaxin-1) and
CCL26 (eotaixn-3) are also crucial for
signalling through their receptor CCR3.
N-terminal truncation of CCL11 or CCL26
generates potent antagonists of their
receptor, CCR3.
Manipulation of the glutaminyl cyclase
pathway represents a novel approach to
CCL2 regulation. However, caution is
warranted before considering a broader
application of such a strategy for the
treatment of inﬂammatory diseases. Pyr-
oglutamic acid is the N-terminal amino
acid of many proteins, hormones and
neurotransmitter peptides, including thyr-
otropin releasinghormone,gonadotropin-
releasing hormone and gastrin (Busby et
al, 1987). Blockade of pE formation by
inhibiting glutaminyl cyclase may there-
fore have untoward side effects in the
nervous and endocrine systems that may
not be predictable. The authors suggest
that the promiscuity of the glutaminyl
cyclase inhibition approach may be a
strength of this therapeutic strategy;
however, this may actually represent a
potential drawback, particularly if one
desires only a speciﬁc block of CCL2 since
allhumanMCPsmaybesubstratesforQC.
Finally,sinceQC/isoQCisaGolgi-resident
enzyme, inhibitors of QC/isoQC need to
act intracellularly, introducing an addi-
tional level of complexity compared to
inhibitors that target extracellular ligands
or receptors. With these caveats in mind,
as additional mechanisms of chemokine
regulationcontinuetobeelucidated,these
discoveries will foster a greater under-
standing of chemokine and chemokine
receptor biology, which will hopefully
lead to the development of new and
exciting agents for the treatment of
inﬂammatory diseases that are both
effective and safe.
The authors declare that they have no
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